Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

ClinicalTrials.gov ID: NCT01907802

Public ClinicalTrials.gov record NCT01907802. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction

Study identification

NCT ID
NCT01907802
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
8 participants

Conditions and interventions

Interventions

  • Dabrafenib Drug
  • Laboratory Biomarker Analysis Other
  • Pharmacogenomic Study Other
  • Pharmacological Study Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 22, 2013
Primary completion
Dec 15, 2015
Completion
Dec 15, 2015
Last update posted
Aug 13, 2018

2013 – 2015

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
City of Hope Comprehensive Cancer Center Duarte California 91010
USC / Norris Comprehensive Cancer Center Los Angeles California 90033
University of California Davis Comprehensive Cancer Center Sacramento California 95817
City of Hope South Pasadena South Pasadena California 91030
University of Colorado Hospital Aurora Colorado 80045
Mayo Clinic in Florida Jacksonville Florida 32224-9980
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287
Dana-Farber Cancer Institute Boston Massachusetts 02215
Wayne State University/Karmanos Cancer Institute Detroit Michigan 48201
Mayo Clinic Rochester Minnesota 55905
Washington University School of Medicine St Louis Missouri 63110
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903
Case Western Reserve University Cleveland Ohio 44106
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232
University of Wisconsin Hospital and Clinics Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01907802, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 13, 2018 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01907802 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →